Pharma & Healthcare
Global Neurological Biomarkers Market Research Report 2026
- Mar 14, 26
- ID: 732011
- Pages: 128
- Figures: 130
- Views: 7
This report delivers a comprehensive overview of the global Neurological Biomarkers market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neurological Biomarkers. The Neurological Biomarkers market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Neurological Biomarkers market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Neurological Biomarkers manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Thermo Fisher Scientific
Merck
Quest Diagnostics
Abbott
Roche
Illumina
Bio-Rad Laboratories
QIAGEN
Myriad RBM
Cisbio Bioassays
Athena Diagnostics
BGI
Wuxi APP
Aepodia
Proteome Sciences
Genewiz
Segment by Type
Proteomics
Genomics
Imaging
Bioinformatics
Others
by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Neurological Biomarkers manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Neurological Biomarkers sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Neurological Biomarkers market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Neurological Biomarkers manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Thermo Fisher Scientific
Merck
Quest Diagnostics
Abbott
Roche
Illumina
Bio-Rad Laboratories
QIAGEN
Myriad RBM
Cisbio Bioassays
Athena Diagnostics
BGI
Wuxi APP
Aepodia
Proteome Sciences
Genewiz
Segment by Type
Proteomics
Genomics
Imaging
Bioinformatics
Others
by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Neurological Biomarkers manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Neurological Biomarkers sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Neurological Biomarkers Market Overview
1.1 Product Definition
1.2 Neurological Biomarkers by Type
1.2.1 Global Neurological Biomarkers Market Value by Type: 2025 vs 2032
1.2.2 Proteomics
1.2.3 Genomics
1.2.4 Imaging
1.2.5 Bioinformatics
1.2.6 Others
1.3 Neurological Biomarkers by Application
1.3.1 Global Neurological Biomarkers Market Value by Application: 2025 vs 2032
1.3.2 Diagnostics
1.3.3 Drug Discovery
1.3.4 Personalized Medicine
1.3.5 Others
1.4 Global Neurological Biomarkers Market Size Estimates and Forecasts
1.4.1 Global Neurological Biomarkers Revenue 2021–2032
1.4.2 Global Neurological Biomarkers Sales 2021–2032
1.4.3 Global Neurological Biomarkers Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Neurological Biomarkers Market Competition by Manufacturers
2.1 Global Neurological Biomarkers Sales Market Share by Manufacturers (2021–2026)
2.2 Global Neurological Biomarkers Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Neurological Biomarkers Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Neurological Biomarkers, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Neurological Biomarkers, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Neurological Biomarkers, Product Types and Applications
2.7 Global Key Manufacturers of Neurological Biomarkers, Date of Entry into the Industry
2.8 Global Neurological Biomarkers Market Competitive Situation and Trends
2.8.1 Global Neurological Biomarkers Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Neurological Biomarkers Players Market Share by Revenue
2.8.3 Global Neurological Biomarkers Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neurological Biomarkers Market Scenario by Region
3.1 Global Neurological Biomarkers Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Neurological Biomarkers Sales by Region: 2021–2032
3.2.1 Global Neurological Biomarkers Sales by Region: 2021–2026
3.2.2 Global Neurological Biomarkers Sales by Region: 2027–2032
3.3 Global Neurological Biomarkers Revenue by Region: 2021–2032
3.3.1 Global Neurological Biomarkers Revenue by Region: 2021–2026
3.3.2 Global Neurological Biomarkers Revenue by Region: 2027–2032
3.4 North America Neurological Biomarkers Market Facts & Figures by Country
3.4.1 North America Neurological Biomarkers Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Neurological Biomarkers Sales by Country (2021–2032)
3.4.3 North America Neurological Biomarkers Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neurological Biomarkers Market Facts & Figures by Country
3.5.1 Europe Neurological Biomarkers Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Neurological Biomarkers Sales by Country (2021–2032)
3.5.3 Europe Neurological Biomarkers Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurological Biomarkers Market Facts & Figures by Region
3.6.1 Asia Pacific Neurological Biomarkers Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Neurological Biomarkers Sales by Region (2021–2032)
3.6.3 Asia Pacific Neurological Biomarkers Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neurological Biomarkers Market Facts & Figures by Country
3.7.1 Latin America Neurological Biomarkers Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Neurological Biomarkers Sales by Country (2021–2032)
3.7.3 Latin America Neurological Biomarkers Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neurological Biomarkers Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurological Biomarkers Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Neurological Biomarkers Sales by Country (2021–2032)
3.8.3 Middle East and Africa Neurological Biomarkers Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Neurological Biomarkers Sales by Type (2021–2032)
4.1.1 Global Neurological Biomarkers Sales by Type (2021–2026)
4.1.2 Global Neurological Biomarkers Sales by Type (2027–2032)
4.1.3 Global Neurological Biomarkers Sales Market Share by Type (2021–2032)
4.2 Global Neurological Biomarkers Revenue by Type (2021–2032)
4.2.1 Global Neurological Biomarkers Revenue by Type (2021–2026)
4.2.2 Global Neurological Biomarkers Revenue by Type (2027–2032)
4.2.3 Global Neurological Biomarkers Revenue Market Share by Type (2021–2032)
4.3 Global Neurological Biomarkers Price by Type (2021–2032)
5 Segment by Application
5.1 Global Neurological Biomarkers Sales by Application (2021–2032)
5.1.1 Global Neurological Biomarkers Sales by Application (2021–2026)
5.1.2 Global Neurological Biomarkers Sales by Application (2027–2032)
5.1.3 Global Neurological Biomarkers Sales Market Share by Application (2021–2032)
5.2 Global Neurological Biomarkers Revenue by Application (2021–2032)
5.2.1 Global Neurological Biomarkers Revenue by Application (2021–2026)
5.2.2 Global Neurological Biomarkers Revenue by Application (2027–2032)
5.2.3 Global Neurological Biomarkers Revenue Market Share by Application (2021–2032)
5.3 Global Neurological Biomarkers Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Thermo Fisher Scientific
6.1.1 Thermo Fisher Scientific Company Information
6.1.2 Thermo Fisher Scientific Description and Business Overview
6.1.3 Thermo Fisher Scientific Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Thermo Fisher Scientific Neurological Biomarkers Product Portfolio
6.1.5 Thermo Fisher Scientific Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Merck Neurological Biomarkers Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Quest Diagnostics
6.3.1 Quest Diagnostics Company Information
6.3.2 Quest Diagnostics Description and Business Overview
6.3.3 Quest Diagnostics Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Quest Diagnostics Neurological Biomarkers Product Portfolio
6.3.5 Quest Diagnostics Recent Developments/Updates
6.4 Abbott
6.4.1 Abbott Company Information
6.4.2 Abbott Description and Business Overview
6.4.3 Abbott Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Abbott Neurological Biomarkers Product Portfolio
6.4.5 Abbott Recent Developments/Updates
6.5 Roche
6.5.1 Roche Company Information
6.5.2 Roche Description and Business Overview
6.5.3 Roche Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Roche Neurological Biomarkers Product Portfolio
6.5.5 Roche Recent Developments/Updates
6.6 Illumina
6.6.1 Illumina Company Information
6.6.2 Illumina Description and Business Overview
6.6.3 Illumina Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Illumina Neurological Biomarkers Product Portfolio
6.6.5 Illumina Recent Developments/Updates
6.7 Bio-Rad Laboratories
6.7.1 Bio-Rad Laboratories Company Information
6.7.2 Bio-Rad Laboratories Description and Business Overview
6.7.3 Bio-Rad Laboratories Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Bio-Rad Laboratories Neurological Biomarkers Product Portfolio
6.7.5 Bio-Rad Laboratories Recent Developments/Updates
6.8 QIAGEN
6.8.1 QIAGEN Company Information
6.8.2 QIAGEN Description and Business Overview
6.8.3 QIAGEN Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 QIAGEN Neurological Biomarkers Product Portfolio
6.8.5 QIAGEN Recent Developments/Updates
6.9 Myriad RBM
6.9.1 Myriad RBM Company Information
6.9.2 Myriad RBM Description and Business Overview
6.9.3 Myriad RBM Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Myriad RBM Neurological Biomarkers Product Portfolio
6.9.5 Myriad RBM Recent Developments/Updates
6.10 Cisbio Bioassays
6.10.1 Cisbio Bioassays Company Information
6.10.2 Cisbio Bioassays Description and Business Overview
6.10.3 Cisbio Bioassays Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Cisbio Bioassays Neurological Biomarkers Product Portfolio
6.10.5 Cisbio Bioassays Recent Developments/Updates
6.11 Athena Diagnostics
6.11.1 Athena Diagnostics Company Information
6.11.2 Athena Diagnostics Description and Business Overview
6.11.3 Athena Diagnostics Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Athena Diagnostics Neurological Biomarkers Product Portfolio
6.11.5 Athena Diagnostics Recent Developments/Updates
6.12 BGI
6.12.1 BGI Company Information
6.12.2 BGI Description and Business Overview
6.12.3 BGI Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 BGI Neurological Biomarkers Product Portfolio
6.12.5 BGI Recent Developments/Updates
6.13 Wuxi APP
6.13.1 Wuxi APP Company Information
6.13.2 Wuxi APP Description and Business Overview
6.13.3 Wuxi APP Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Wuxi APP Neurological Biomarkers Product Portfolio
6.13.5 Wuxi APP Recent Developments/Updates
6.14 Aepodia
6.14.1 Aepodia Company Information
6.14.2 Aepodia Description and Business Overview
6.14.3 Aepodia Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Aepodia Neurological Biomarkers Product Portfolio
6.14.5 Aepodia Recent Developments/Updates
6.15 Proteome Sciences
6.15.1 Proteome Sciences Company Information
6.15.2 Proteome Sciences Description and Business Overview
6.15.3 Proteome Sciences Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Proteome Sciences Neurological Biomarkers Product Portfolio
6.15.5 Proteome Sciences Recent Developments/Updates
6.16 Genewiz
6.16.1 Genewiz Company Information
6.16.2 Genewiz Description and Business Overview
6.16.3 Genewiz Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Genewiz Neurological Biomarkers Product Portfolio
6.16.5 Genewiz Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurological Biomarkers Industry Chain Analysis
7.2 Neurological Biomarkers Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurological Biomarkers Production Mode & Process Analysis
7.4 Neurological Biomarkers Sales and Marketing
7.4.1 Neurological Biomarkers Sales Channels
7.4.2 Neurological Biomarkers Distributors
7.5 Neurological Biomarkers Customer Analysis
8 Neurological Biomarkers Market Dynamics
8.1 Neurological Biomarkers Industry Trends
8.2 Neurological Biomarkers Market Drivers
8.3 Neurological Biomarkers Market Challenges
8.4 Neurological Biomarkers Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Neurological Biomarkers by Type
1.2.1 Global Neurological Biomarkers Market Value by Type: 2025 vs 2032
1.2.2 Proteomics
1.2.3 Genomics
1.2.4 Imaging
1.2.5 Bioinformatics
1.2.6 Others
1.3 Neurological Biomarkers by Application
1.3.1 Global Neurological Biomarkers Market Value by Application: 2025 vs 2032
1.3.2 Diagnostics
1.3.3 Drug Discovery
1.3.4 Personalized Medicine
1.3.5 Others
1.4 Global Neurological Biomarkers Market Size Estimates and Forecasts
1.4.1 Global Neurological Biomarkers Revenue 2021–2032
1.4.2 Global Neurological Biomarkers Sales 2021–2032
1.4.3 Global Neurological Biomarkers Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Neurological Biomarkers Market Competition by Manufacturers
2.1 Global Neurological Biomarkers Sales Market Share by Manufacturers (2021–2026)
2.2 Global Neurological Biomarkers Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Neurological Biomarkers Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Neurological Biomarkers, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Neurological Biomarkers, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Neurological Biomarkers, Product Types and Applications
2.7 Global Key Manufacturers of Neurological Biomarkers, Date of Entry into the Industry
2.8 Global Neurological Biomarkers Market Competitive Situation and Trends
2.8.1 Global Neurological Biomarkers Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Neurological Biomarkers Players Market Share by Revenue
2.8.3 Global Neurological Biomarkers Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neurological Biomarkers Market Scenario by Region
3.1 Global Neurological Biomarkers Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Neurological Biomarkers Sales by Region: 2021–2032
3.2.1 Global Neurological Biomarkers Sales by Region: 2021–2026
3.2.2 Global Neurological Biomarkers Sales by Region: 2027–2032
3.3 Global Neurological Biomarkers Revenue by Region: 2021–2032
3.3.1 Global Neurological Biomarkers Revenue by Region: 2021–2026
3.3.2 Global Neurological Biomarkers Revenue by Region: 2027–2032
3.4 North America Neurological Biomarkers Market Facts & Figures by Country
3.4.1 North America Neurological Biomarkers Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Neurological Biomarkers Sales by Country (2021–2032)
3.4.3 North America Neurological Biomarkers Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neurological Biomarkers Market Facts & Figures by Country
3.5.1 Europe Neurological Biomarkers Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Neurological Biomarkers Sales by Country (2021–2032)
3.5.3 Europe Neurological Biomarkers Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurological Biomarkers Market Facts & Figures by Region
3.6.1 Asia Pacific Neurological Biomarkers Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Neurological Biomarkers Sales by Region (2021–2032)
3.6.3 Asia Pacific Neurological Biomarkers Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neurological Biomarkers Market Facts & Figures by Country
3.7.1 Latin America Neurological Biomarkers Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Neurological Biomarkers Sales by Country (2021–2032)
3.7.3 Latin America Neurological Biomarkers Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neurological Biomarkers Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurological Biomarkers Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Neurological Biomarkers Sales by Country (2021–2032)
3.8.3 Middle East and Africa Neurological Biomarkers Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Neurological Biomarkers Sales by Type (2021–2032)
4.1.1 Global Neurological Biomarkers Sales by Type (2021–2026)
4.1.2 Global Neurological Biomarkers Sales by Type (2027–2032)
4.1.3 Global Neurological Biomarkers Sales Market Share by Type (2021–2032)
4.2 Global Neurological Biomarkers Revenue by Type (2021–2032)
4.2.1 Global Neurological Biomarkers Revenue by Type (2021–2026)
4.2.2 Global Neurological Biomarkers Revenue by Type (2027–2032)
4.2.3 Global Neurological Biomarkers Revenue Market Share by Type (2021–2032)
4.3 Global Neurological Biomarkers Price by Type (2021–2032)
5 Segment by Application
5.1 Global Neurological Biomarkers Sales by Application (2021–2032)
5.1.1 Global Neurological Biomarkers Sales by Application (2021–2026)
5.1.2 Global Neurological Biomarkers Sales by Application (2027–2032)
5.1.3 Global Neurological Biomarkers Sales Market Share by Application (2021–2032)
5.2 Global Neurological Biomarkers Revenue by Application (2021–2032)
5.2.1 Global Neurological Biomarkers Revenue by Application (2021–2026)
5.2.2 Global Neurological Biomarkers Revenue by Application (2027–2032)
5.2.3 Global Neurological Biomarkers Revenue Market Share by Application (2021–2032)
5.3 Global Neurological Biomarkers Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Thermo Fisher Scientific
6.1.1 Thermo Fisher Scientific Company Information
6.1.2 Thermo Fisher Scientific Description and Business Overview
6.1.3 Thermo Fisher Scientific Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Thermo Fisher Scientific Neurological Biomarkers Product Portfolio
6.1.5 Thermo Fisher Scientific Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Merck Neurological Biomarkers Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Quest Diagnostics
6.3.1 Quest Diagnostics Company Information
6.3.2 Quest Diagnostics Description and Business Overview
6.3.3 Quest Diagnostics Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Quest Diagnostics Neurological Biomarkers Product Portfolio
6.3.5 Quest Diagnostics Recent Developments/Updates
6.4 Abbott
6.4.1 Abbott Company Information
6.4.2 Abbott Description and Business Overview
6.4.3 Abbott Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Abbott Neurological Biomarkers Product Portfolio
6.4.5 Abbott Recent Developments/Updates
6.5 Roche
6.5.1 Roche Company Information
6.5.2 Roche Description and Business Overview
6.5.3 Roche Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Roche Neurological Biomarkers Product Portfolio
6.5.5 Roche Recent Developments/Updates
6.6 Illumina
6.6.1 Illumina Company Information
6.6.2 Illumina Description and Business Overview
6.6.3 Illumina Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Illumina Neurological Biomarkers Product Portfolio
6.6.5 Illumina Recent Developments/Updates
6.7 Bio-Rad Laboratories
6.7.1 Bio-Rad Laboratories Company Information
6.7.2 Bio-Rad Laboratories Description and Business Overview
6.7.3 Bio-Rad Laboratories Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Bio-Rad Laboratories Neurological Biomarkers Product Portfolio
6.7.5 Bio-Rad Laboratories Recent Developments/Updates
6.8 QIAGEN
6.8.1 QIAGEN Company Information
6.8.2 QIAGEN Description and Business Overview
6.8.3 QIAGEN Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 QIAGEN Neurological Biomarkers Product Portfolio
6.8.5 QIAGEN Recent Developments/Updates
6.9 Myriad RBM
6.9.1 Myriad RBM Company Information
6.9.2 Myriad RBM Description and Business Overview
6.9.3 Myriad RBM Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Myriad RBM Neurological Biomarkers Product Portfolio
6.9.5 Myriad RBM Recent Developments/Updates
6.10 Cisbio Bioassays
6.10.1 Cisbio Bioassays Company Information
6.10.2 Cisbio Bioassays Description and Business Overview
6.10.3 Cisbio Bioassays Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Cisbio Bioassays Neurological Biomarkers Product Portfolio
6.10.5 Cisbio Bioassays Recent Developments/Updates
6.11 Athena Diagnostics
6.11.1 Athena Diagnostics Company Information
6.11.2 Athena Diagnostics Description and Business Overview
6.11.3 Athena Diagnostics Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Athena Diagnostics Neurological Biomarkers Product Portfolio
6.11.5 Athena Diagnostics Recent Developments/Updates
6.12 BGI
6.12.1 BGI Company Information
6.12.2 BGI Description and Business Overview
6.12.3 BGI Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 BGI Neurological Biomarkers Product Portfolio
6.12.5 BGI Recent Developments/Updates
6.13 Wuxi APP
6.13.1 Wuxi APP Company Information
6.13.2 Wuxi APP Description and Business Overview
6.13.3 Wuxi APP Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Wuxi APP Neurological Biomarkers Product Portfolio
6.13.5 Wuxi APP Recent Developments/Updates
6.14 Aepodia
6.14.1 Aepodia Company Information
6.14.2 Aepodia Description and Business Overview
6.14.3 Aepodia Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Aepodia Neurological Biomarkers Product Portfolio
6.14.5 Aepodia Recent Developments/Updates
6.15 Proteome Sciences
6.15.1 Proteome Sciences Company Information
6.15.2 Proteome Sciences Description and Business Overview
6.15.3 Proteome Sciences Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Proteome Sciences Neurological Biomarkers Product Portfolio
6.15.5 Proteome Sciences Recent Developments/Updates
6.16 Genewiz
6.16.1 Genewiz Company Information
6.16.2 Genewiz Description and Business Overview
6.16.3 Genewiz Neurological Biomarkers Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Genewiz Neurological Biomarkers Product Portfolio
6.16.5 Genewiz Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurological Biomarkers Industry Chain Analysis
7.2 Neurological Biomarkers Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurological Biomarkers Production Mode & Process Analysis
7.4 Neurological Biomarkers Sales and Marketing
7.4.1 Neurological Biomarkers Sales Channels
7.4.2 Neurological Biomarkers Distributors
7.5 Neurological Biomarkers Customer Analysis
8 Neurological Biomarkers Market Dynamics
8.1 Neurological Biomarkers Industry Trends
8.2 Neurological Biomarkers Market Drivers
8.3 Neurological Biomarkers Market Challenges
8.4 Neurological Biomarkers Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Neurological Biomarkers Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Neurological Biomarkers Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Neurological Biomarkers Market Competitive Situation by Manufacturers in 2025
Table 4. Global Neurological Biomarkers Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Neurological Biomarkers Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Neurological Biomarkers Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Neurological Biomarkers Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Neurological Biomarkers Average Price (USD/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Neurological Biomarkers, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Neurological Biomarkers, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Neurological Biomarkers, Product Types and Applications
Table 12. Global Key Manufacturers of Neurological Biomarkers, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Neurological Biomarkers Companies by Tier (Tier 1, Tier 2, Tier 3), based on Neurological Biomarkers Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Neurological Biomarkers Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Neurological Biomarkers Sales by Region (K Units), 2021–2026
Table 18. Global Neurological Biomarkers Sales Market Share by Region (2021–2026)
Table 19. Global Neurological Biomarkers Sales by Region (K Units), 2027–2032
Table 20. Global Neurological Biomarkers Sales Market Share by Region (2027–2032)
Table 21. Global Neurological Biomarkers Revenue by Region (US$ Million), 2021–2026
Table 22. Global Neurological Biomarkers Revenue Market Share by Region (2021–2026)
Table 23. Global Neurological Biomarkers Revenue by Region (US$ Million), 2027–2032
Table 24. Global Neurological Biomarkers Revenue Market Share by Region (2027–2032)
Table 25. North America Neurological Biomarkers Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Neurological Biomarkers Sales by Country (K Units), 2021–2026
Table 27. North America Neurological Biomarkers Sales by Country (K Units), 2027–2032
Table 28. North America Neurological Biomarkers Revenue by Country (US$ Million), 2021–2026
Table 29. North America Neurological Biomarkers Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Neurological Biomarkers Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Neurological Biomarkers Sales by Country (K Units), 2021–2026
Table 32. Europe Neurological Biomarkers Sales by Country (K Units), 2027–2032
Table 33. Europe Neurological Biomarkers Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Neurological Biomarkers Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Neurological Biomarkers Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Neurological Biomarkers Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Neurological Biomarkers Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Neurological Biomarkers Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Neurological Biomarkers Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Neurological Biomarkers Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Neurological Biomarkers Sales by Country (K Units), 2021–2026
Table 42. Latin America Neurological Biomarkers Sales by Country (K Units), 2027–2032
Table 43. Latin America Neurological Biomarkers Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Neurological Biomarkers Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Neurological Biomarkers Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Neurological Biomarkers Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Neurological Biomarkers Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Neurological Biomarkers Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Neurological Biomarkers Revenue by Country (US$ Million), 2027–2032
Table 50. Global Neurological Biomarkers Sales (K Units) by Type (2021–2026)
Table 51. Global Neurological Biomarkers Sales (K Units) by Type (2027–2032)
Table 52. Global Neurological Biomarkers Sales Market Share by Type (2021–2026)
Table 53. Global Neurological Biomarkers Sales Market Share by Type (2027–2032)
Table 54. Global Neurological Biomarkers Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Neurological Biomarkers Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Neurological Biomarkers Revenue Market Share by Type (2021–2026)
Table 57. Global Neurological Biomarkers Revenue Market Share by Type (2027–2032)
Table 58. Global Neurological Biomarkers Price (USD/Unit) by Type (2021–2026)
Table 59. Global Neurological Biomarkers Price (USD/Unit) by Type (2027–2032)
Table 60. Global Neurological Biomarkers Sales (K Units) by Application (2021–2026)
Table 61. Global Neurological Biomarkers Sales (K Units) by Application (2027–2032)
Table 62. Global Neurological Biomarkers Sales Market Share by Application (2021–2026)
Table 63. Global Neurological Biomarkers Sales Market Share by Application (2027–2032)
Table 64. Global Neurological Biomarkers Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Neurological Biomarkers Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Neurological Biomarkers Revenue Market Share by Application (2021–2026)
Table 67. Global Neurological Biomarkers Revenue Market Share by Application (2027–2032)
Table 68. Global Neurological Biomarkers Price (USD/Unit) by Application (2021–2026)
Table 69. Global Neurological Biomarkers Price (USD/Unit) by Application (2027–2032)
Table 70. Thermo Fisher Scientific Company Information
Table 71. Thermo Fisher Scientific Description and Business Overview
Table 72. Thermo Fisher Scientific Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 73. Thermo Fisher Scientific Neurological Biomarkers Product
Table 74. Thermo Fisher Scientific Recent Developments/Updates
Table 75. Merck Company Information
Table 76. Merck Description and Business Overview
Table 77. Merck Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 78. Merck Neurological Biomarkers Product
Table 79. Merck Recent Developments/Updates
Table 80. Quest Diagnostics Company Information
Table 81. Quest Diagnostics Description and Business Overview
Table 82. Quest Diagnostics Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 83. Quest Diagnostics Neurological Biomarkers Product
Table 84. Quest Diagnostics Recent Developments/Updates
Table 85. Abbott Company Information
Table 86. Abbott Description and Business Overview
Table 87. Abbott Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 88. Abbott Neurological Biomarkers Product
Table 89. Abbott Recent Developments/Updates
Table 90. Roche Company Information
Table 91. Roche Description and Business Overview
Table 92. Roche Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 93. Roche Neurological Biomarkers Product
Table 94. Roche Recent Developments/Updates
Table 95. Illumina Company Information
Table 96. Illumina Description and Business Overview
Table 97. Illumina Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 98. Illumina Neurological Biomarkers Product
Table 99. Illumina Recent Developments/Updates
Table 100. Bio-Rad Laboratories Company Information
Table 101. Bio-Rad Laboratories Description and Business Overview
Table 102. Bio-Rad Laboratories Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 103. Bio-Rad Laboratories Neurological Biomarkers Product
Table 104. Bio-Rad Laboratories Recent Developments/Updates
Table 105. QIAGEN Company Information
Table 106. QIAGEN Description and Business Overview
Table 107. QIAGEN Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 108. QIAGEN Neurological Biomarkers Product
Table 109. QIAGEN Recent Developments/Updates
Table 110. Myriad RBM Company Information
Table 111. Myriad RBM Description and Business Overview
Table 112. Myriad RBM Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 113. Myriad RBM Neurological Biomarkers Product
Table 114. Myriad RBM Recent Developments/Updates
Table 115. Cisbio Bioassays Company Information
Table 116. Cisbio Bioassays Description and Business Overview
Table 117. Cisbio Bioassays Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 118. Cisbio Bioassays Neurological Biomarkers Product
Table 119. Cisbio Bioassays Recent Developments/Updates
Table 120. Athena Diagnostics Company Information
Table 121. Athena Diagnostics Description and Business Overview
Table 122. Athena Diagnostics Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 123. Athena Diagnostics Neurological Biomarkers Product
Table 124. Athena Diagnostics Recent Developments/Updates
Table 125. BGI Company Information
Table 126. BGI Description and Business Overview
Table 127. BGI Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 128. BGI Neurological Biomarkers Product
Table 129. BGI Recent Developments/Updates
Table 130. Wuxi APP Company Information
Table 131. Wuxi APP Description and Business Overview
Table 132. Wuxi APP Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 133. Wuxi APP Neurological Biomarkers Product
Table 134. Wuxi APP Recent Developments/Updates
Table 135. Aepodia Company Information
Table 136. Aepodia Description and Business Overview
Table 137. Aepodia Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 138. Aepodia Neurological Biomarkers Product
Table 139. Aepodia Recent Developments/Updates
Table 140. Proteome Sciences Company Information
Table 141. Proteome Sciences Description and Business Overview
Table 142. Proteome Sciences Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 143. Proteome Sciences Neurological Biomarkers Product
Table 144. Proteome Sciences Recent Developments/Updates
Table 145. Genewiz Company Information
Table 146. Genewiz Description and Business Overview
Table 147. Genewiz Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 148. Genewiz Neurological Biomarkers Product
Table 149. Genewiz Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Neurological Biomarkers Distributors List
Table 153. Neurological Biomarkers Customers List
Table 154. Neurological Biomarkers Market Trends
Table 155. Neurological Biomarkers Market Drivers
Table 156. Neurological Biomarkers Market Challenges
Table 157. Neurological Biomarkers Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
Table 161. Authors List of This Report
List of Figures
Figure 1. Product Picture of Neurological Biomarkers
Figure 2. Global Neurological Biomarkers Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Neurological Biomarkers Market Share by Type: 2025 & 2032
Figure 4. Proteomics Product Picture
Figure 5. Genomics Product Picture
Figure 6. Imaging Product Picture
Figure 7. Bioinformatics Product Picture
Figure 8. Others Product Picture
Figure 9. Global Neurological Biomarkers Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Neurological Biomarkers Market Share by Application: 2025 & 2032
Figure 11. Diagnostics
Figure 12. Drug Discovery
Figure 13. Personalized Medicine
Figure 14. Others
Figure 15. Global Neurological Biomarkers Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Neurological Biomarkers Market Size (US$ Million), 2021–2032
Figure 17. Global Neurological Biomarkers Sales (K Units), 2021–2032
Figure 18. Global Neurological Biomarkers Average Price (USD/Unit), 2021–2032
Figure 19. Neurological Biomarkers Report Years Considered
Figure 20. Neurological Biomarkers Sales Share by Manufacturers in 2025
Figure 21. Global Neurological Biomarkers Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global Neurological Biomarkers Players: Market Share by Revenue in Neurological Biomarkers in 2025
Figure 23. Neurological Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global Neurological Biomarkers Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America Neurological Biomarkers Sales Market Share by Country (2021–2032)
Figure 26. North America Neurological Biomarkers Revenue Market Share by Country (2021–2032)
Figure 27. U.S. Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe Neurological Biomarkers Sales Market Share by Country (2021–2032)
Figure 30. Europe Neurological Biomarkers Revenue Market Share by Country (2021–2032)
Figure 31. Germany Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific Neurological Biomarkers Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific Neurological Biomarkers Revenue Market Share by Region (2021–2032)
Figure 38. China Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Taiwan Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Indonesia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Thailand Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Malaysia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Philippines Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Latin America Neurological Biomarkers Sales Market Share by Country (2021–2032)
Figure 49. Latin America Neurological Biomarkers Revenue Market Share by Country (2021–2032)
Figure 50. Mexico Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Brazil Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Argentina Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Middle East and Africa Neurological Biomarkers Sales Market Share by Country (2021–2032)
Figure 54. Middle East and Africa Neurological Biomarkers Revenue Market Share by Country (2021–2032)
Figure 55. Turkey Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Saudi Arabia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. U.A.E Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Global Sales Market Share of Neurological Biomarkers by Type (2021–2032)
Figure 59. Global Revenue Market Share of Neurological Biomarkers by Type (2021–2032)
Figure 60. Global Neurological Biomarkers Price (USD/Unit) by Type (2021–2032)
Figure 61. Global Sales Market Share of Neurological Biomarkers by Application (2021–2032)
Figure 62. Global Revenue Market Share of Neurological Biomarkers by Application (2021–2032)
Figure 63. Global Neurological Biomarkers Price (USD/Unit) by Application (2021–2032)
Figure 64. Neurological Biomarkers Value Chain
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Table 1. Global Neurological Biomarkers Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Neurological Biomarkers Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Neurological Biomarkers Market Competitive Situation by Manufacturers in 2025
Table 4. Global Neurological Biomarkers Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Neurological Biomarkers Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Neurological Biomarkers Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Neurological Biomarkers Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Neurological Biomarkers Average Price (USD/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Neurological Biomarkers, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Neurological Biomarkers, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Neurological Biomarkers, Product Types and Applications
Table 12. Global Key Manufacturers of Neurological Biomarkers, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Neurological Biomarkers Companies by Tier (Tier 1, Tier 2, Tier 3), based on Neurological Biomarkers Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Neurological Biomarkers Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Neurological Biomarkers Sales by Region (K Units), 2021–2026
Table 18. Global Neurological Biomarkers Sales Market Share by Region (2021–2026)
Table 19. Global Neurological Biomarkers Sales by Region (K Units), 2027–2032
Table 20. Global Neurological Biomarkers Sales Market Share by Region (2027–2032)
Table 21. Global Neurological Biomarkers Revenue by Region (US$ Million), 2021–2026
Table 22. Global Neurological Biomarkers Revenue Market Share by Region (2021–2026)
Table 23. Global Neurological Biomarkers Revenue by Region (US$ Million), 2027–2032
Table 24. Global Neurological Biomarkers Revenue Market Share by Region (2027–2032)
Table 25. North America Neurological Biomarkers Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Neurological Biomarkers Sales by Country (K Units), 2021–2026
Table 27. North America Neurological Biomarkers Sales by Country (K Units), 2027–2032
Table 28. North America Neurological Biomarkers Revenue by Country (US$ Million), 2021–2026
Table 29. North America Neurological Biomarkers Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Neurological Biomarkers Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Neurological Biomarkers Sales by Country (K Units), 2021–2026
Table 32. Europe Neurological Biomarkers Sales by Country (K Units), 2027–2032
Table 33. Europe Neurological Biomarkers Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Neurological Biomarkers Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Neurological Biomarkers Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Neurological Biomarkers Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Neurological Biomarkers Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Neurological Biomarkers Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Neurological Biomarkers Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Neurological Biomarkers Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Neurological Biomarkers Sales by Country (K Units), 2021–2026
Table 42. Latin America Neurological Biomarkers Sales by Country (K Units), 2027–2032
Table 43. Latin America Neurological Biomarkers Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Neurological Biomarkers Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Neurological Biomarkers Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Neurological Biomarkers Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Neurological Biomarkers Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Neurological Biomarkers Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Neurological Biomarkers Revenue by Country (US$ Million), 2027–2032
Table 50. Global Neurological Biomarkers Sales (K Units) by Type (2021–2026)
Table 51. Global Neurological Biomarkers Sales (K Units) by Type (2027–2032)
Table 52. Global Neurological Biomarkers Sales Market Share by Type (2021–2026)
Table 53. Global Neurological Biomarkers Sales Market Share by Type (2027–2032)
Table 54. Global Neurological Biomarkers Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Neurological Biomarkers Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Neurological Biomarkers Revenue Market Share by Type (2021–2026)
Table 57. Global Neurological Biomarkers Revenue Market Share by Type (2027–2032)
Table 58. Global Neurological Biomarkers Price (USD/Unit) by Type (2021–2026)
Table 59. Global Neurological Biomarkers Price (USD/Unit) by Type (2027–2032)
Table 60. Global Neurological Biomarkers Sales (K Units) by Application (2021–2026)
Table 61. Global Neurological Biomarkers Sales (K Units) by Application (2027–2032)
Table 62. Global Neurological Biomarkers Sales Market Share by Application (2021–2026)
Table 63. Global Neurological Biomarkers Sales Market Share by Application (2027–2032)
Table 64. Global Neurological Biomarkers Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Neurological Biomarkers Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Neurological Biomarkers Revenue Market Share by Application (2021–2026)
Table 67. Global Neurological Biomarkers Revenue Market Share by Application (2027–2032)
Table 68. Global Neurological Biomarkers Price (USD/Unit) by Application (2021–2026)
Table 69. Global Neurological Biomarkers Price (USD/Unit) by Application (2027–2032)
Table 70. Thermo Fisher Scientific Company Information
Table 71. Thermo Fisher Scientific Description and Business Overview
Table 72. Thermo Fisher Scientific Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 73. Thermo Fisher Scientific Neurological Biomarkers Product
Table 74. Thermo Fisher Scientific Recent Developments/Updates
Table 75. Merck Company Information
Table 76. Merck Description and Business Overview
Table 77. Merck Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 78. Merck Neurological Biomarkers Product
Table 79. Merck Recent Developments/Updates
Table 80. Quest Diagnostics Company Information
Table 81. Quest Diagnostics Description and Business Overview
Table 82. Quest Diagnostics Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 83. Quest Diagnostics Neurological Biomarkers Product
Table 84. Quest Diagnostics Recent Developments/Updates
Table 85. Abbott Company Information
Table 86. Abbott Description and Business Overview
Table 87. Abbott Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 88. Abbott Neurological Biomarkers Product
Table 89. Abbott Recent Developments/Updates
Table 90. Roche Company Information
Table 91. Roche Description and Business Overview
Table 92. Roche Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 93. Roche Neurological Biomarkers Product
Table 94. Roche Recent Developments/Updates
Table 95. Illumina Company Information
Table 96. Illumina Description and Business Overview
Table 97. Illumina Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 98. Illumina Neurological Biomarkers Product
Table 99. Illumina Recent Developments/Updates
Table 100. Bio-Rad Laboratories Company Information
Table 101. Bio-Rad Laboratories Description and Business Overview
Table 102. Bio-Rad Laboratories Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 103. Bio-Rad Laboratories Neurological Biomarkers Product
Table 104. Bio-Rad Laboratories Recent Developments/Updates
Table 105. QIAGEN Company Information
Table 106. QIAGEN Description and Business Overview
Table 107. QIAGEN Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 108. QIAGEN Neurological Biomarkers Product
Table 109. QIAGEN Recent Developments/Updates
Table 110. Myriad RBM Company Information
Table 111. Myriad RBM Description and Business Overview
Table 112. Myriad RBM Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 113. Myriad RBM Neurological Biomarkers Product
Table 114. Myriad RBM Recent Developments/Updates
Table 115. Cisbio Bioassays Company Information
Table 116. Cisbio Bioassays Description and Business Overview
Table 117. Cisbio Bioassays Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 118. Cisbio Bioassays Neurological Biomarkers Product
Table 119. Cisbio Bioassays Recent Developments/Updates
Table 120. Athena Diagnostics Company Information
Table 121. Athena Diagnostics Description and Business Overview
Table 122. Athena Diagnostics Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 123. Athena Diagnostics Neurological Biomarkers Product
Table 124. Athena Diagnostics Recent Developments/Updates
Table 125. BGI Company Information
Table 126. BGI Description and Business Overview
Table 127. BGI Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 128. BGI Neurological Biomarkers Product
Table 129. BGI Recent Developments/Updates
Table 130. Wuxi APP Company Information
Table 131. Wuxi APP Description and Business Overview
Table 132. Wuxi APP Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 133. Wuxi APP Neurological Biomarkers Product
Table 134. Wuxi APP Recent Developments/Updates
Table 135. Aepodia Company Information
Table 136. Aepodia Description and Business Overview
Table 137. Aepodia Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 138. Aepodia Neurological Biomarkers Product
Table 139. Aepodia Recent Developments/Updates
Table 140. Proteome Sciences Company Information
Table 141. Proteome Sciences Description and Business Overview
Table 142. Proteome Sciences Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 143. Proteome Sciences Neurological Biomarkers Product
Table 144. Proteome Sciences Recent Developments/Updates
Table 145. Genewiz Company Information
Table 146. Genewiz Description and Business Overview
Table 147. Genewiz Neurological Biomarkers Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 148. Genewiz Neurological Biomarkers Product
Table 149. Genewiz Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Neurological Biomarkers Distributors List
Table 153. Neurological Biomarkers Customers List
Table 154. Neurological Biomarkers Market Trends
Table 155. Neurological Biomarkers Market Drivers
Table 156. Neurological Biomarkers Market Challenges
Table 157. Neurological Biomarkers Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
Table 161. Authors List of This Report
List of Figures
Figure 1. Product Picture of Neurological Biomarkers
Figure 2. Global Neurological Biomarkers Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Neurological Biomarkers Market Share by Type: 2025 & 2032
Figure 4. Proteomics Product Picture
Figure 5. Genomics Product Picture
Figure 6. Imaging Product Picture
Figure 7. Bioinformatics Product Picture
Figure 8. Others Product Picture
Figure 9. Global Neurological Biomarkers Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Neurological Biomarkers Market Share by Application: 2025 & 2032
Figure 11. Diagnostics
Figure 12. Drug Discovery
Figure 13. Personalized Medicine
Figure 14. Others
Figure 15. Global Neurological Biomarkers Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Neurological Biomarkers Market Size (US$ Million), 2021–2032
Figure 17. Global Neurological Biomarkers Sales (K Units), 2021–2032
Figure 18. Global Neurological Biomarkers Average Price (USD/Unit), 2021–2032
Figure 19. Neurological Biomarkers Report Years Considered
Figure 20. Neurological Biomarkers Sales Share by Manufacturers in 2025
Figure 21. Global Neurological Biomarkers Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global Neurological Biomarkers Players: Market Share by Revenue in Neurological Biomarkers in 2025
Figure 23. Neurological Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global Neurological Biomarkers Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America Neurological Biomarkers Sales Market Share by Country (2021–2032)
Figure 26. North America Neurological Biomarkers Revenue Market Share by Country (2021–2032)
Figure 27. U.S. Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe Neurological Biomarkers Sales Market Share by Country (2021–2032)
Figure 30. Europe Neurological Biomarkers Revenue Market Share by Country (2021–2032)
Figure 31. Germany Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific Neurological Biomarkers Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific Neurological Biomarkers Revenue Market Share by Region (2021–2032)
Figure 38. China Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Taiwan Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Indonesia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Thailand Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Malaysia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Philippines Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Latin America Neurological Biomarkers Sales Market Share by Country (2021–2032)
Figure 49. Latin America Neurological Biomarkers Revenue Market Share by Country (2021–2032)
Figure 50. Mexico Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Brazil Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Argentina Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Middle East and Africa Neurological Biomarkers Sales Market Share by Country (2021–2032)
Figure 54. Middle East and Africa Neurological Biomarkers Revenue Market Share by Country (2021–2032)
Figure 55. Turkey Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Saudi Arabia Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. U.A.E Neurological Biomarkers Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Global Sales Market Share of Neurological Biomarkers by Type (2021–2032)
Figure 59. Global Revenue Market Share of Neurological Biomarkers by Type (2021–2032)
Figure 60. Global Neurological Biomarkers Price (USD/Unit) by Type (2021–2032)
Figure 61. Global Sales Market Share of Neurological Biomarkers by Application (2021–2032)
Figure 62. Global Revenue Market Share of Neurological Biomarkers by Application (2021–2032)
Figure 63. Global Neurological Biomarkers Price (USD/Unit) by Application (2021–2032)
Figure 64. Neurological Biomarkers Value Chain
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232